Overview

This trial is active, not recruiting.

Condition head and neck cancer
Treatments gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, flow cytometry, laboratory biomarker analysis
Sponsor Vanderbilt-Ingram Cancer Center
Collaborator National Cancer Institute (NCI)
Start date March 2004
End date December 2010
Trial size 400 participants
Trial identifier NCT00482872, CDR0000546713, VICC-IRB-040030, VU-VICC-HN-0402

Summary

RATIONALE: Studying gene mutations in samples of DNA from patients with head and neck cancer and a family history of cancer may help doctors learn more about the development of cancer in families.

PURPOSE: This clinical trial is studying germline mutations in patients with head and neck cancer and a family history of cancer.

United States No locations recruiting
Other Countries No locations recruiting

Primary Outcomes

Measure
Incidence of INK4a-p16 germline mutations
time frame:
Biologic activity of identified INK4a-p16 germline mutations
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Diagnosis of squamous cell carcinoma (SCC) of the head and neck - Must have ≥ 1 first-degree relative with any of the following cancers: - Non-small cell lung cancer - Melanoma - Pancreatic cancer - SCC of the head and neck - Lymphoma (controls) PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified

Additional Information

Official title Familial HNSCC Syndrome and p16 Germline Mutations
Description OBJECTIVES: - Measure the incidence of p16^INK4a germline mutations in patients with squamous cell carcinoma of the head and neck and a family history of cancer. - Determine biologic activity of identified p16^INK4a germline mutations. OUTLINE: DNA specimens are collected for genetic and mutation analysis and examined by PCR and flow cytometry. The activity of cells with p16 mutations is determined by cell cycle arrest functional assay.
Trial information was received from ClinicalTrials.gov and was last updated in February 2010.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).